Journal
LUTS-LOWER URINARY TRACT SYMPTOMS
Volume 10, Issue 2, Pages 109-115Publisher
WILEY
DOI: 10.1111/luts.12163
Keywords
Botulinum toxin A; sphincter; quality of life; urinary retention; urodynamics
Categories
Funding
- Allergan, Ltd.
- Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award
- King's College London
- King's College Hospital NHS Foundation Trust
Ask authors/readers for more resources
The first reported application of Botulinum toxin-A (BTX-A) into the urethral sphincter predates the first documented use in the bladder. The aim of this review is to describe the clinical indications of BTX-A injection into the urethral sphincter and its clinical efficacy. This review of the literature includes the larger more significant published studies that have reported on this use of BTX-A. Case reports and articles not published in English were excluded. There have been many published clinical studies describing the use of BTX-A in the urethral sphincter, four of which are randomized placebo controlled trials. These studies tend to include patients either in urinary retention or with obstructed voiding, both in the neuropathic and non-neuropathic populations. Studies tend to demonstrate improvements in urodynamic parameters and quality of life after injection. There have been many small clinical studies in this area, however larger placebo-controlled trials are needed to evaluate this treatment at higher levels of evidence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available